Cancer genetics & genomics; omics technologies including nanopore and single cell sequencing; circulating tumour DNA; bioinformatics; organoid models; faecal transplantation, immunogenomics especially HLA typing
Current research projects:
MOL-SRC: Molecular determinants of radiosensitivity in rectal cancer - exploring the phenomenon of complete response to neoadjuvant chemoradiotherapy in rectal cancer using organoid models and omics technologies
ORB-AZ: Utilising organoid models of cancer to understand the response mechanisms and resistance patterns in immune engager molecules in colorectal, lung and prostate cancer
International Sarcoma Accelerator Consortium: utilising omics to understand mechanisms of treatment resistance in soft tissue sarcoma and develop new neoadjuvant therapies.
Oesophageal Cancer Clinical and Molecular Subtyping consortium (OCCAMS): utilising omics to understand the pathogenesis of gastro-oesophageal cancer
Long read HLA typing: development of IP protected methodology for full length sequencing of the HLA class I, II and III genes using nanopore sequencing
Nanopore sequencing method development: collaborating with industrial partners to develop new methods of applying long read sequencing to cancer and human biology.
My laboratory acts as scientific leads and carries out the translational scientific research for:
DETERMINE – National Rare Tumours stratified medicine trial – my laboratory is carrying out all the omics for this landmark study
FOXTROT2/3/4 – neoadjuvant chemotherapy in colorectal cancer
STAR-TREC – organ preservation in rectal cancer
ARIEL - A biomarker enrichment trial of anti-EGFR agents in right primary tumor location (rPTL), RAS wild-type (RAS-wt) advanced colorectal cancer (aCRC)
FARGO – Using FMT to slow the progress of primary sclerosing cholangitis (https://www.pscsupport.org.uk/the-fargo-trial/)
STOP-COLITIS – Using FMT to treat treatment resistance ulcerative colitis